3-carbethoxypsoralen

Known as: 3-carbethoxy-psoralen, 7H-furo(3,2-g)(1)benzopyran-3-carboxylic acid, 7-oxo-, ethyl ester 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1978-2014
051019782014

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1994
1994
The complementation and genetical analysis of yeast mutants sensitive to photoactivated 3-carbethoxy-psoralen define three novel… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
1994
1994
The furocourmarins 3-carbethoxypsoralen (3-CP) and 4,4',6-trimethylangelicin (TMA) were generally believed to be incapable of… (More)
Is this relevant?
1993
1993
The specific recognition of DNA modifications by repair endonucleases was used to characterize damage induced by 3… (More)
Is this relevant?
1989
1989
DNA photosensitization by several furocoumarins (including 3-carbethoxypsoralen (3-CPs), 8-methoxypsoralen (8-MOP), 5… (More)
Is this relevant?
1987
1987
An experimental design to simulate PUVA therapy (oral 8-methoxypsoralen followed by uv radiation) has been tested in a 13-week… (More)
Is this relevant?
1984
1984
Furocoumarins (psoralens) are potent skin photosensitizing agents that are used in combination with long-wavelength ultraviolet… (More)
Is this relevant?
1983
1983
Cell survival, i.e. colony-forming ability, and the induction of 6-thioguanine-resistant (6-TGr) mutants were determined in… (More)
Is this relevant?
1982
1982
8-methoxypsoralen (8-MOP) and 3-Carbethoxypsoralen (3-CPs) are known photoreagents which have been employed in the treatment of… (More)
  • figure 1
  • figure 3
Is this relevant?
1980
1980
Reverse and forward mutation, induced by photoaddition of 8-methoxypsoralen (8-MOP) and 3-carbethoxypsoralen (3-CPs) or… (More)
  • figure 1
  • figure 3
  • figure 4
  • figure 5
  • figure 6
Is this relevant?
1979
1979
The carcinogenic risk of photochemotherapy (PUVA) with bi-functional furocoumarins such as 8-methoxypsoralen (8-MOP) which form… (More)
Is this relevant?